System4 Technologies
\nGmbH<\/a> has developed a new therapy device for the treatment of Covid patients.<\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
The device, named PI-RNA, is designed to enable
\nuniversal and fast deactivation of coronaviruses and influenza viruses, their
\nmutations and new variants by means of \u00a0a special cold atmospheric plasma procedure.
\n“The so-called CAP (Cold Atmospheric Plasma) \u2013 technology transfers
\nelectrostatically atmospheric anions, in high numbers and densities, into and
\naround the body of the patient. This is achieved through a newly developed
\nplasma design and transfer procedure that we have developed in the past eight
\nmonths”, says Ilir Guslo, Managing Director of System4 Technologies GmbH. “The
\natmospheric anions, which are transferred in a gentle and non-invasive manner,
\ncontain reactive electrons that are presumed to interact with all variants of
\nthe coronavirus and influenza viruses, and inactivate them”, states Guslo
\nfurther.<\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
In the scientific hypothesis, the anions group
\naround the spike proteins of the virus. This accumulation of ions around the
\nspike proteins causes highly reactive hydroxyl radicals (OH\u00b7) to form. These
\nreact with the spike proteins and withdraw hydrogen from them, whereby water
\n(H2O) is formed from the hydroxyl radicals (OH\u00b7) and the hydrogen (H). The loss
\nof hydrogen damages the spike proteins, rendering them incapable of infecting
\nhuman cells. The PI-RNA device is intended for use in intensive care medicine
\nto achieve a significant reduction of the viral load in the lungs, mouth and
\npharynx, and to support a fast regeneration of the patient. The developers also
\nenvisage effective post-therapeutic use of the device for the treatment of late
\nsymptoms of COVID-19, also known as long COVID. Research into the use of cold
\natmospheric plasma on coronaviruses has been conducted for a considerable time
\nat the Max Planck Institute and the Fraunhofer Institute for Toxicology and
\nExperimental Medicine. <\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
However, before PI-RNA can be used, the
\nhypothesis and promising initial indications from off-label-use applications in
\nHungary must be confirmed and scientifically verified by a two-phase
\ndouble-blind study. <\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
“Together with a highly respected clinical research
\npartner, we are planning to start the phase I clinical study in mid-2021, to
\nrun simultaneously at three national and international sites”, says Dr Benjamin
\nSeibt, of Genomics, scientific partner of the project. <\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
Due to the dynamic development of potentially
\nharmful Sars-CoV-2 mutations and new variants, worldwide focus has shifted to
\nuniversal active agents and therapies to fight the pandemic and for the
\npost-pandemic period.<\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
System4 Technologies is hoping to produce swift
\nresults and solutions, thereby contributing toward a universal virus therapy.<\/p>\n
\n
<\/p>\n
\u00a0<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Initial
off-label-use applications with a special plasma design are promising. Possible use in
intensive care medicine and treatment of long COVID. Planned
large-scale study on universal use against coronaviruses and other RNA viruses.
BAD ZWISCHENAHN, GERMANY – EQS Newswire – 26 April
2021 – The life science company System4 Technologies
GmbH has developed …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/14235"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=14235"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/14235\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=14235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=14235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=14235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}